









Markets
/
Stocks
/
nasdaq-uncy
/

Unicycive Therapeutics Inc

UNCY

4.150USD

+0.130+3.23%

Close 09/29, 16:00（ET）Quotes delayed by 15 min

58.56MMarket Cap

LossP/E TTM



Unicycive Therapeutics Inc

4.150

+0.130+3.23%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Unicycive Therapeutics Inc

Currency: USD Updated: 2025-09-29

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Unicycive Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

135 / 505

Overall Ranking

245 / 4714

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

63.125

Target Price

+1470.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Unicycive Therapeutics Inc Highlights

StrengthsRisks

Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 109.46.

Undervalued

The company’s latest PE is -1.49, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 6.96M shares, decreasing 8.61% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 605.95K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.79.

Financial Health

Currency: USD Updated: 2025-09-29

The company's current financial score is 3.94, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

3.94

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

0.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

0.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.70

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

5.00

Key Metrics

Free cash flow

No Data

Unicycive Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-09-29

The company’s current valuation score is 7.33, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -1.49, which is -1134.39% below the recent high of 15.42 and -49.90% above the recent low of -2.23.

Score

Industry at a Glance

Previous score

7.33

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 135/505

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-29

The company’s current earnings forecast score is 8.25, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Unicycive Therapeutics Inc is 60.00, with a high of 105.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

8.25

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

63.125

Target Price

+1470.27%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Unicycive Therapeutics Inc

UNCY

CRISPR Therapeutics AG

CRSP

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-29

The company’s current price momentum score is 8.95, which is higher than the Biotechnology & Medical Research industry's average of 6.76. Sideways: Currently, the stock price is trading between the resistance level at 4.48 and the support level at 3.76, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.32

Change

1.63

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.001

Neutral

RSI(14)

52.091

Neutral

STOCH(KDJ)(9,3,3)

57.476

Buy

ATR(14)

0.233

High Vlolatility

CCI(14)

82.445

Neutral

Williams %R

36.232

Buy

TRIX(12,20)

-0.365

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

3.948

Buy

MA10

3.978

Buy

MA20

4.100

Buy

MA50

4.240

Sell

MA100

3.379

Buy

MA200

2.001

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-29

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.97. The latest institutional shareholding proportion is 54.51%, representing a quarter-over-quarter decrease of 15.48%. The largest institutional shareholder is The Vanguard, holding a total of 605.95K shares, representing 3.43% of shares outstanding, with 243.16% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Vivo Capital, LLC

1.14M

+14.04%

Octagon Capital Advisors LP

1.00M

Nantahala Capital Management, LLC

939.20K

-9.62%

Great Point Partners, LLC

1.10M

The Vanguard Group, Inc.

Star Investors

121.24K

+6.52%

Gupta (Shalabh K)

597.25K

-0.02%

Logos Global Management LP

507.89K

Rosalind Advisors, Inc.

242.49K

Armistice Capital LLC

97.60K

Acuta Capital Partners, LLC

235.29K

+2.17%

Risk Assessment

Currency: USD Updated: 2025-09-29

The company’s current risk assessment score is 3.36, which is lower than the Biotechnology & Medical Research industry's average of 3.49. The company's beta value is 1.85. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.